Article: Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleSerum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus
AuthorsMok, MY1
Huang, FP3
Ip, WK4
Lo, Y1
Wong, FY4
Chan, EYT4
Lam, KF1
Xu, D2
KeywordsInterleukin-33
Soluble ST2
Systemic lupus erythematosus disease activity index
T helper 2 immune response
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
CitationRheumatology, 2009, v. 49 n. 3, p. 520-527 [How to Cite?]
DOI: http://dx.doi.org/10.1093/rheumatology/kep402
AbstractObjective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P<0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.
ISSN1462-0324
2011 Impact Factor: 4.058
2011 SCImago Journal Rankings: 0.353
DOIhttp://dx.doi.org/10.1093/rheumatology/kep402
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorMok, MY
dc.contributor.authorHuang, FP
dc.contributor.authorIp, WK
dc.contributor.authorLo, Y
dc.contributor.authorWong, FY
dc.contributor.authorChan, EYT
dc.contributor.authorLam, KF
dc.contributor.authorXu, D
dc.date.accessioned2012-09-05T05:29:50Z
dc.date.available2012-09-05T05:29:50Z
dc.date.issued2009
dc.description.abstractObjective. IL-33 has recently been found to be the specific ligand of ST2, an IL-1 receptor family member that is selectively expressed in Th2 cells and mediates Th2 response. This study aims to measure the serum levels of soluble ST2 (sST2) and IL-33 in patients with SLE and to examine their association with disease activity. Methods. Seventy SLE patients were evaluated for disease activity, determined by SLEDAI, levels of anti-dsDNA antibody, C3 and C4. Fifty-seven patients were evaluated longitudinally on a second occasion. IL-33 and sST2 were measured by sandwich ELISA in the 127 SLE serum samples and compared with 28 age-and sex-matched healthy controls. Results. Serum sST2 level was significantly higher in active SLE patients [0.51 (0.18) ng/ml] compared with inactive patients [0.42 (0.08) ng/ml] (P = 0.006) and normal controls [0.36 (0.13) ng/ml] (P<0.001). sST2 level correlated significantly with SLEDAI, anti-dsDNA antibody and prednisolone dosage, and negatively with C3. Linear regression analysis showed that serum sST2 level was an independent predictive factor for modified SLEDAI, excluding anti-dsDNA and complement score after controlling for age, sex, glomerular filtration rate and prednisolone dosage (regression coefficient: 8.5; 95% CI 2.6, 14.3) (P = 0.005). Serum sST2 level was sensitive to change in disease activity longitudinally, with an effect size of 0.29. Elevated serum IL-33 was comparable in frequency (4.3 vs 7.1%; P = 0.62) and levels (P = 0.53) between SLE patients and controls. Conclusions. Elevated serum sST2 level in SLE patients was found to correlate with disease activity and was sensitive to change, suggesting a potential role as a surrogate marker of disease activity. © The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationRheumatology, 2009, v. 49 n. 3, p. 520-527 [How to Cite?]
DOI: http://dx.doi.org/10.1093/rheumatology/kep402
dc.identifier.doihttp://dx.doi.org/10.1093/rheumatology/kep402
dc.identifier.epage527
dc.identifier.issn1462-0324
2011 Impact Factor: 4.058
2011 SCImago Journal Rankings: 0.353
dc.identifier.issue3
dc.identifier.pmid20026564
dc.identifier.scopuseid_2-s2.0-77950534152
dc.identifier.spage520
dc.identifier.urihttp://hdl.handle.net/10722/163300
dc.identifier.volume49
dc.languageeng
dc.publisherOxford University Press. The Journal's web site is located at http://rheumatology.oxfordjournals.org/
dc.publisher.placeUnited Kingdom
dc.relation.ispartofRheumatology
dc.relation.referencesReferences in Scopus
dc.subject.meshAdult
dc.subject.meshAntibodies, Antinuclear - Blood
dc.subject.meshBiological Markers - Blood
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshEpidemiologic Methods
dc.subject.meshFemale
dc.subject.meshGlucocorticoids - Administration & Dosage
dc.subject.meshHumans
dc.subject.meshImmunosuppressive Agents - Administration & Dosage
dc.subject.meshInterleukins - Blood
dc.subject.meshLupus Erythematosus, Systemic - Drug Therapy - Immunology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrednisolone - Administration & Dosage
dc.subject.meshReceptors, Cell Surface - Blood
dc.subjectInterleukin-33
dc.subjectSoluble ST2
dc.subjectSystemic lupus erythematosus disease activity index
dc.subjectT helper 2 immune response
dc.titleSerum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. University of Glasgow
  3. Imperial College London
  4. Queen Mary Hospital Hong Kong